In a report released today, Mitchell Kapoor from H.C. Wainwright initiated coverage with a Buy rating on Instil Bio (TIL – Research Report) and a price target of $2.00. The company’s shares closed yesterday at $0.54.
Kapoor covers the Healthcare sector, focusing on stocks such as Legend Biotech, Rain Therapeutics, and Rallybio. According to TipRanks, Kapoor has an average return of 1.5% and a 48.94% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Instil Bio with a $3.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Instil Bio’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $57.07 million. In comparison, last year the company had a GAAP net loss of $54.12 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
Read More on TIL:
